Why the study?
Mortality and morbidity remain high following TAVR in dialysis patients or those with low LVEF, and therapeutic strategies for patients with these comorbidities remain unestablished.
A period of optimal medical therapy to induce reverse remodeling may facilitate successful trans-apical TAVR in high-risk dialysis patients with low ejection fraction.
Answers are grounded in this paper and cite their sources.
Successful TAVR after OMT-induced remodeling may be feasible in select dialysis patients with low LVEF; leaves open need for prospective validation.
Mortality and morbidity remain high following transcatheter aortic valve replacement (TAVR) in dialysis patients or those with low left ventricular ejection fraction. Therapeutic strategy for those with these comorbidities remains unestablished. We had a dialysis patient with peripheral artery disease and low left ventricular ejection fraction, who received successfully scheduled trans-apical TAVR following sufficient reverse remodeling by 3-month optimal medical therapy. Our strategy should be validated in a larger robust cohort.
No takes yet. Share an insight, caveat, or question.
Oshima et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: